Inhalon Biopharma is developing inhaled monoclonal antibody treatments for acute respiratory infections, including RSV and SARS-CoV-2, utilizing a novel inhalation delivery system. This approach aims to enhance treatment effectiveness and provide a convenient "test-to-treat" model for patients, facilitating timely and accessible respiratory care.
Funding
$11.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFounders
Product
Problem
Acute respiratory infections like RSV, influenza, and SARS-CoV-2 pose a significant threat, particularly to vulnerable populations. Current treatments often require intravenous administration in a clinical setting, limiting accessibility and delaying timely intervention. This can lead to increased disease severity, longer hospital stays, and higher healthcare costs.
Solution
Inhalon Biopharma is developing inhaled monoclonal antibody therapies designed for rapid and convenient treatment of acute respiratory infections. Their proprietary inhalation delivery system allows for direct delivery of antibodies to the respiratory tract, potentially enhancing treatment effectiveness and reducing systemic exposure. This approach supports a "test-to-treat" model, enabling patients to receive immediate treatment at home or in a point-of-care setting, improving access to care and potentially preventing disease progression.
Target Audience
The primary target audience includes individuals at high risk of complications from acute respiratory infections, such as the elderly, immunocompromised individuals, and those with underlying respiratory conditions, as well as healthcare providers seeking more effective and accessible treatment options.
Features
- Proprietary inhaled formulation of monoclonal antibodies targeting common respiratory viruses
- Direct delivery to the respiratory tract for enhanced local efficacy
- Convenient and non-invasive administration via a portable inhalation device
- Streamlined "test-to-treat" model for rapid intervention
- Potential for at-home or point-of-care treatment, improving accessibility